These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32840856)

  • 1. Coronavirus Human Infection Challenge Studies: Assessing Potential Benefits and Risks.
    Jamrozik E; Heriot GS; Selgelid MJ
    J Bioeth Inq; 2020 Dec; 17(4):709-715. PubMed ID: 32840856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 human challenge studies: ethical issues.
    Jamrozik E; Selgelid MJ
    Lancet Infect Dis; 2020 Aug; 20(8):e198-e203. PubMed ID: 32479747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. So much at stake: Ethical tradeoffs in accelerating SARSCoV-2 vaccine development.
    Grady C; Shah S; Miller F; Danis M; Nicolini M; Ochoa J; Taylor H; Wendler D; Rid A
    Vaccine; 2020 Sep; 38(41):6381-6387. PubMed ID: 32826103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues.
    Baay M; Neels P
    Biologicals; 2020 Sep; 67():69-74. PubMed ID: 32829985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure.
    Eyal N; Lipsitch M; Smith PG
    J Infect Dis; 2020 May; 221(11):1752-1756. PubMed ID: 32232474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethics of controlled human infection to address COVID-19.
    Shah SK; Miller FG; Darton TC; Duenas D; Emerson C; Lynch HF; Jamrozik E; Jecker NS; Kamuya D; Kapulu M; Kimmelman J; MacKay D; Memoli MJ; Murphy SC; Palacios R; Richie TL; Roestenberg M; Saxena A; Saylor K; Selgelid MJ; Vaswani V; Rid A
    Science; 2020 May; 368(6493):832-834. PubMed ID: 32381590
    [No Abstract]   [Full Text] [Related]  

  • 8. Controlled Human Infection to Speed Up SARS-CoV-2 Vaccine Development.
    Baay M; Neels P
    Front Immunol; 2021; 12():658783. PubMed ID: 33777056
    [No Abstract]   [Full Text] [Related]  

  • 9. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 vaccine development: Time to consider SARS-CoV-2 challenge studies?
    Schaefer GO; Tam CC; Savulescu J; Voo TC
    Vaccine; 2020 Jul; 38(33):5085-5088. PubMed ID: 32540271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 challenge studies: ethics and risk minimisation.
    Bull S; Jamrozik E; Binik A; Parker MJ
    J Med Ethics; 2020 Sep; 47(12):e79. PubMed ID: 32978304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project).
    Korang SK; Juul S; Nielsen EE; Feinberg J; Siddiqui F; Ong G; Klingenberg S; Veroniki AA; Bu F; Thabane L; Thomsen AR; Jakobsen JC; Gluud C
    Syst Rev; 2020 Nov; 9(1):262. PubMed ID: 33218366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.
    Mirzaei R; Mohammadzadeh R; Mahdavi F; Badrzadeh F; Kazemi S; Ebrahimi M; Soltani F; Kazemi S; Jeda AS; Darvishmotevalli M; Yousefimashouf R; Keyvani H; Karampoor S
    Int Immunopharmacol; 2020 Nov; 88():106928. PubMed ID: 32862110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant protein vaccines, a proven approach against coronavirus pandemics.
    Pollet J; Chen WH; Strych U
    Adv Drug Deliv Rev; 2021 Mar; 170():71-82. PubMed ID: 33421475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Covid-19 vaccine trial protocols released.
    Doshi P
    BMJ; 2020 Oct; 371():m4058. PubMed ID: 33087395
    [No Abstract]   [Full Text] [Related]  

  • 16. COVID-19 vaccines: ethical framework concerning human challenge studies.
    Calina D; Hartung T; Docea AO; Spandidos DA; Egorov AM; Shtilman MI; Carvalho F; Tsatsakis A
    Daru; 2020 Dec; 28(2):807-812. PubMed ID: 32851596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV prevention research and COVID-19: putting ethics guidance to the test.
    Rennie S; Chege W; Schrumpf LA; Luna F; Klitzman R; Moseki E; Brown B; Wakefield S; Sugarman J
    BMC Med Ethics; 2021 Jan; 22(1):6. PubMed ID: 33494754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Priority allocation of pandemic influenza vaccines in Australia - Recommendations of 3 community juries.
    Degeling C; Williams J; Carter SM; Moss R; Massey P; Gilbert GL; Shih P; Braunack-Mayer A; Crooks K; Brown D; McVernon J
    Vaccine; 2021 Jan; 39(2):255-262. PubMed ID: 33317870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 2020 race towards SARS-CoV-2 specific vaccines.
    Karpiński TM; Ożarowski M; Seremak-Mrozikiewicz A; Wolski H; Wlodkowic D
    Theranostics; 2021; 11(4):1690-1702. PubMed ID: 33408775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Universal screening for SARS-CoV-2 infection: a rapid review.
    Viswanathan M; Kahwati L; Jahn B; Giger K; Dobrescu AI; Hill C; Klerings I; Meixner J; Persad E; Teufer B; Gartlehner G
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD013718. PubMed ID: 33502003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.